Science and Ethics at NIH--and FDA

Many of the headlines suggested that the proposed ethics rules for NIH employees have been relaxed. But that's not quite true, as Ted Agres pointed out here. The rules on stock ownership have loosened, yes. But the most important restriction remains. That's the one forbidding those who labor at NIH to do outside consulting for businesses with a stake in NIH's labor.These decisions are a smart move for NIH director Elias A. Zerhouni. The previous proposed stock ownership rules were needl

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Many of the headlines suggested that the proposed ethics rules for NIH employees have been relaxed. But that's not quite true, as Ted Agres pointed out here. The rules on stock ownership have loosened, yes. But the most important restriction remains. That's the one forbidding those who labor at NIH to do outside consulting for businesses with a stake in NIH's labor.These decisions are a smart move for NIH director Elias A. Zerhouni. The previous proposed stock ownership rules were needlessly restrictive on most employees. The new stock rules will please them, yet also retain some restrictions on NIH's most senior people. It looks to be a sensible compromise that will reduce opportunities for mischief while making it somewhat less difficult to recruit world-class scientists. But Zerhouni stood firm against the activities that offer the most serious opportunities for corruption of the scientific process: outside consulting for pharmas, biotechs, and related industries. That's the right thing to do, and it's also smart PR. It can't hurt NIH's reputation with the public--or with Congress--that Zerhouni seems serious about trying to keep the agency's science pure.By contrast, on Friday the FDA once again postponed a decision on allowing nonprescription sales of Plan B, the morning-after contraceptive. This is still another craven cave-in to political pressure from the religious right--to say nothing of a repudiation of the scientific committees whose advice the agency is supposed to be taking, which favored wider availability. In these Washington Dog Days, displaying even a little backbone, as Zerhouni did, makes him look like a candidate for canonization.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Tabitha M. Powledge

    This person does not yet have a bio.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo